Expression of ERCC1 and class IIIβ tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer

Pathology International

Volumn 59, Issue 12, 2009, Pages 863-867

  Ikeda, Satoshi ^a   Takabe, Kazuhiko ^a   Suzuki, Keiko ^a  

^a TSUCHIURA KYODO GENERAL HOSPITAL   (Japan)

Author keywords

Chemotherapy; Class III tubulin; ERCC1; Non small cell lung cancer

Indexed keywords

BETA TUBULIN; CARBOPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOPSY; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; TUBULIN;

EID: 71049134390     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2009.02463.x     Document Type: Article

References (24)

1. Pritchard KI. The best use of adjuvant endocrine treatments. Breast 2003 12 : 497 508.
2. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res 2002 30 : 3848 3856.
3. Dabholkar M, Bostick-Bruton F, Weber C et al. Expression of excision repair genes in non-malignant bone marrow from cancer patients. Mutat Res 1993 293 : 151 160.
4. Cobo M, Isla D, Massuti B et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer. J Clin Oncol 2007 25 : 2747 2754.
5. Sève P, Isaac S, Trédan O et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005 11 : 5481 5486. (Pubitemid 41060824)
6. Dumontet C, Isaac S, Souquet PJ et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005 92 : E25 30.
7. Sève P, Mackey J, Isaac S et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005 4 : 2001 2007. (Pubitemid 43056983)
8. Azuma K, Sasada T, Kawahara A et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol 2009 64 : 565 573.
9. Lord RV, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002 8 : 2286 2291.
10. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005 127 : 978 983.
11. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006 355 : 983 991.
12. Booton R, Ward T, Ashcroft L et al. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007 2 : 902 906.
13. Zheng Z, Chen T, Li X et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007 356 : 800 808.
14. Azuma K, Komohara Y, Sasada T et al. Excision repair cross- complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 2007 98 : 1336 1343.
15. Fujii T, Toyooka S, Ichimura K et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 2008 59 : 377 384.
16. Hwang IG, Ahn MJ, Park BB et al. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 2008 113 : 1379 1386.
17. Ota S, Ishii G, Goto K et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 2009 64 : 98 104.
18. Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005 50 : 211 219.
19. Hayashi Y, Kuriyama H, Umezu H et al. Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern Med 2009 48 : 203 208.
20. Urano N, Fujiwara Y, Doki Y et al. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 2006 28 : 375 381.
21. Sève P, Reiman T, Isaac S et al. Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. Anticancer Res 2008 28 : 1161 1167.
22. Azuma K, Sasada T, Kawahara A et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009 64 : 326 333.
23. Okuda K, Sasaki H, Dumontet C et al. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 2008 62 : 105 112.
24. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004 351 : 337 345.